a study to assess the effectiveness of sunscreen on oil control, moisturization, and skin barrier integrity in adults with oily skin

Conditions: Oily Skin

Summary: the purpose of this trial is to evaluate 1) the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics through a) instrumental measurements, b) expert grader and c) perceived efficacy; 2) the efficacy of an investigational product in reducing oiliness, improving hydration, the pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use through instrumental measurements and perceived efficacy questionnaires.

the objectives of this study are: to evaluate the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics: * instrumental measurements with the sebumeter® sm 815 equipment to assess oiliness control; * clinical efficacy evaluation carried out by expert grader * perceived efficacy through perception questionnaires to evaluate the efficacy of an investigational product in reducing oiliness, improving hydration, pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use, under normal conditions of use in adult participants through the following evaluations: * instrumental measurements with the sebumeter® sm 815 equipment before and after 7 and 28 ± 2 days of use on the face to assess oil reduction; * instrumental measurements with the corneometer® before and after 7 and 28 ± 2 days of use on the face to assess skin hydration; * instrumental measurements with the tewameter® tm 300 before and after 7 and 28 ± 2 days of use on the face to assess the integrity/maintenance of the skin barrier; * facial images captured using visia® cr equipment before and after 7 and 28 ± 2 days of use on the face; * perceived efficacy through perception questionnaires answered by research participants after 7 and 28 ± 2 days of use on the face; * open-ended emotional statement after 28 ± 2 days.

Eligibility criteria:
inclusion criteria: * men and/or women; * 18 to 55 years old; * phototypes i to vi according to the fitzpatrick classification; * subjects of any ethnicity according to brazilian institute of geography and statistics (ibge) criteria * integral skin in the test areas; * subjects with oily skin, confirmed by instrumental measurements: (sebumetry value of at least 100μg/cm² in the frontal region (average of 3 measurements)). * subjects with face oil shine - confirmed by dermatologist; * subjects with enlarged pores on the face - confirmed by a dermatologist; * subjects with self-perceived combination/oily or very oily skin on the face; * subjects with a self-perceived oil shine on the face; * subjects with self-perceived enlarged pores on the face; * do not use cosmetic products (including usual soap) the night before the visit and do not wash your face after 10 p.m. the day before the visit; * for male subjects: who agree to shave 48 hours before the visits; * generally, in good health based on medical history reported by the subject; * subjects able to read, write, speak, and understand portuguese; * agreeing to adhere to the procedures and requirements of the study and attending the site on the day(s) and time(s) set for the evaluations; * subjects who signed the terms informed consent document (icd) and informed consent image disclosure (icid); * intends to complete the study and is willing and able to follow all the study instructions. exclusion criteria: * has known allergies or adverse reactions to common topical skin care products including sunscreens; * presents a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer); * have primary/secondary lesions (e.g. scars, ulcers, vesicles) or tattoos in the test areas; * has self-reported type 1 or type 2 diabetes or is taking insulin or another anti-diabetic medication; * is taking a medication that would mask an adverse event (ae) or confound the study results, including: * immunosuppressive or steroidal drugs within 2 months before visit 1\* * non-steroidal anti-inflammatory drugs within 5 days before visit 1\* (for oxaprozin and piroxicam consider 2 weeks before visit 1). * antihistamines within 2 weeks before visit 1\* \*if an individual is taking one of these medication types, the individual is not considered eligible at screening. however, if a subject begins using one of these medications during the study, the study physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "concurrent/concomitant medication". * use of any other products capable of interfering with the study evaluations, at the discretion of the dermatologist; * subjects who have undergone invasive aesthetic or dermatological treatment in the test area within 2 months prior to the start of the study or during the study; * subjects who had used cosmetic products to treat oiliness/shine on the same area (face) within 14 days prior to the start of the study; * subjects who are using any medication to treat diseases of the face or eyes; * subjects who reported being pregnant, or planning to become pregnant during the study; * has a history of or a concurrent health condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study; * simultaneously taking part in another study; * being an employee/contractor or close relative of the principal investigator, study site, or sponsor; * excessive hair in the assessment area that could interfere with instrumental measurements.